Lepu Biopharma Co., Ltd. (HKG: 2157)
Hong Kong
· Delayed Price · Currency is HKD 3.400
-0.180 (-5.03%)
Oct 10, 2024, 4:08 PM HKT
Lepu Biopharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 205.08 | 225.35 | 15.57 | - | - | - |
| Revenue Growth (YoY) | 21.26% | 1347.16% | - | - | - | - |
| Cost of Revenue | 43.56 | 28.28 | 2.01 | - | - | - |
| Gross Profit | 161.52 | 197.08 | 13.57 | - | - | - |
| Selling, General & Admin | 151.66 | 129.95 | 140.58 | 156.24 | 93.76 | 191.55 |
| Research & Development | 442.81 | 458.07 | 524.29 | 791.21 | 354.43 | 229.2 |
| Other Operating Expenses | 5.79 | -0.38 | -8.85 | -3.77 | -0.73 | -2.3 |
| Operating Expenses | 600.26 | 587.65 | 656.02 | 943.68 | 447.45 | 418.45 |
| Operating Income | -438.74 | -390.57 | -642.45 | -943.68 | -447.45 | -418.45 |
| Interest Expense | -15.22 | -14.68 | -7.47 | -2.7 | -85.21 | -52.32 |
| Interest & Investment Income | 5.31 | 8.18 | 8.35 | 9.1 | 10.36 | 2.43 |
| Earnings From Equity Investments | -12.88 | -27.34 | -32.23 | -17.7 | -12.08 | -8.68 |
| Currency Exchange Gain (Loss) | 0.12 | 0.21 | 37.75 | -2.41 | 0.04 | 0 |
| Other Non Operating Income (Expenses) | 155.79 | 173.64 | -64 | -76.86 | -1.11 | -0.24 |
| EBT Excluding Unusual Items | -305.61 | -250.56 | -700.05 | -1,034 | -535.46 | -477.25 |
| Gain (Loss) on Sale of Investments | 220.26 | 220.26 | - | 5.37 | -77.99 | -38.31 |
| Gain (Loss) on Sale of Assets | -0.01 | - | 0.61 | - | - | 0.07 |
| Pretax Income | -85.36 | -30.3 | -699.44 | -1,029 | -613.45 | -515.49 |
| Earnings From Continuing Operations | -85.36 | -30.3 | -699.44 | -1,029 | -613.45 | -515.49 |
| Minority Interest in Earnings | 12.74 | 8.21 | 10.39 | 17.87 | 31.6 | 68.46 |
| Net Income | -72.62 | -22.1 | -689.05 | -1,011 | -581.85 | -447.04 |
| Net Income to Common | -72.62 | -22.1 | -689.05 | -1,011 | -581.85 | -447.04 |
| Shares Outstanding (Basic) | 1,665 | 1,659 | 1,641 | 1,520 | 1,135 | 649 |
| Shares Outstanding (Diluted) | 1,665 | 1,659 | 1,641 | 1,520 | 1,135 | 649 |
| Shares Change (YoY) | 0.31% | 1.13% | 7.92% | 33.97% | 74.89% | - |
| EPS (Basic) | -0.04 | -0.01 | -0.42 | -0.66 | -0.51 | -0.69 |
| EPS (Diluted) | -0.04 | -0.01 | -0.42 | -0.66 | -0.51 | -0.69 |
| Free Cash Flow | -312.71 | -278.84 | -591.38 | -835.12 | -661.95 | -552.47 |
| Free Cash Flow Per Share | -0.19 | -0.17 | -0.36 | -0.55 | -0.58 | -0.85 |
| Gross Margin | 78.76% | 87.45% | 87.12% | - | - | - |
| Operating Margin | -213.93% | -173.32% | -4125.67% | - | - | - |
| Profit Margin | -35.41% | -9.81% | -4424.94% | - | - | - |
| Free Cash Flow Margin | -152.48% | -123.73% | -3797.71% | - | - | - |
| EBITDA | -367.8 | -306.66 | -564.63 | -866.49 | -383.76 | -382.32 |
| EBITDA Margin | -179.34% | -136.08% | - | - | - | - |
| D&A For EBITDA | 70.94 | 83.91 | 77.82 | 77.18 | 63.69 | 36.13 |
| EBIT | -438.74 | -390.57 | -642.45 | -943.68 | -447.45 | -418.45 |
| EBIT Margin | -213.93% | -173.32% | - | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.